Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis A Systematic Review

被引:61
|
作者
Mueller, Jannis [1 ,2 ,3 ,4 ]
Cagol, Alessandro [1 ,2 ,3 ]
Lorscheider, Johannes [1 ,2 ,4 ]
Tsagkas, Charidimos [1 ,2 ,3 ,4 ]
Benkert, Pascal [5 ]
Yaldizli, Ozgur [1 ,2 ,3 ,4 ]
Kuhle, Jens [1 ,2 ,4 ]
Derfuss, Tobias [1 ,2 ,4 ]
Sormani, Maria Pia [6 ,7 ]
Thompson, Alan [8 ,9 ]
Granziera, Cristina [1 ,2 ,3 ,4 ]
Kappos, Ludwig [1 ,2 ,3 ,10 ]
机构
[1] Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland
[2] Univ Basel, Basel, Switzerland
[3] Univ Hosp Basel, Fac Med, Dept Biomed Engn, Translat Imaging Neurol ThINK Basel, Basel, Switzerland
[4] Univ Hosp Basel, Dept Biomed, Neurol Clin & Policlin, Basel, Switzerland
[5] Univ Basel, Univ Hosp Basel, Dept Clin Res, Clin Trial Unit, Basel, Switzerland
[6] IRCCS Osped Policlin San Martino, Dept Hlth Sci, I-16132 Genoa, Italy
[7] IRCCS Osped Policlin San Martino, Genoa, Italy
[8] UCL Inst Neurol, Queen Sq MS Ctr, London, England
[9] NIHR Univ Coll London Hosp, Biomed Res Ctr, London, England
[10] Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Spitalstr 2, CH-4031 Basel, Switzerland
关键词
DISABILITY PROGRESSION; ONSET; PIRA; ACCUMULATION; OCRELIZUMAB; AGE;
D O I
10.1001/jamaneurol.2023.3331
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ImportanceEmerging evidence suggests that progression independent of relapse activity (PIRA) is a substantial contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (RRMS). To date, there is no uniform agreed-upon definition of PIRA, limiting the comparability of published studies.ObjectiveTo summarize the current evidence about PIRA based on a systematic review, to discuss the various terminologies used in the context of PIRA, and to propose a harmonized definition for PIRA for use in clinical practice and future trials.Evidence ReviewA literature search was conducted using the search terms multiple sclerosis, PIRA, progression independent of relapse activity, silent progression, and progression unrelated to relapses in PubMed, Embase, Cochrane, and Web of Science, published between January 1990 and December 2022.FindingsOf 119 identified single records, 48 eligible studies were analyzed. PIRA was reported to occur in roughly 5% of all patients with RRMS per annum, causing at least 50% of all disability accrual events in typical RRMS. The proportion of PIRA vs relapse-associated worsening increased with age, longer disease duration, and, despite lower absolute event numbers, potent suppression of relapses by highly effective disease-modifying therapy. However, different studies used various definitions of PIRA, rendering the comparability of studies difficult.Conclusion and RelevancePIRA is the most frequent manifestation of disability accumulation across the full spectrum of traditional MS phenotypes, including clinically isolated syndrome and early RRMS. The harmonized definition suggested here may improve the comparability of results in current and future cohorts and data sets.
引用
收藏
页码:1232 / 1245
页数:14
相关论文
共 50 条
  • [31] Systematic Review of Cognitive Dysfunction in Pediatric and Juvenile Multiple Sclerosis
    Cardoso, Mariana
    Olmo, Neide Regina
    Fragoso, Yara Dadalti
    PEDIATRIC NEUROLOGY, 2015, 53 (04) : 287 - 292
  • [32] Systematic review of prediction models in relapsing remitting multiple sclerosis
    Brown, Fraser S.
    Glasmacher, Stella A.
    Kearns, Patrick K. A.
    MacDougall, Niall
    Hunt, David
    Connick, Peter
    Chandran, Siddharthan
    PLOS ONE, 2020, 15 (05):
  • [33] Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis
    Sucksdorff, Marcus
    Matilainen, Markus
    Tuisku, Jouni
    Polvinen, Eero
    Vuorimaa, Anna
    Rokka, Johanna
    Nylund, Marjo
    Rissanen, Eero
    Airas, Laura
    BRAIN, 2020, 143 : 3318 - 3330
  • [34] Risk factors for unprovoked epileptic seizures in multiple sclerosis: a systematic review and meta-analysis
    Gasparini, Sara
    Ferlazzo, Edoardo
    Ascoli, Michele
    Sueri, Chiara
    Cianci, Vittoria
    Russo, Concetta
    Pisani, Laura Rosa
    Striano, Pasquale
    Elia, Maurizio
    Beghi, Ettore
    Colica, Carmela
    Aguglia, Umberto
    NEUROLOGICAL SCIENCES, 2017, 38 (03) : 399 - 406
  • [35] Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review
    Sellner, Johann
    Rommer, Paulus S.
    AUTOIMMUNITY REVIEWS, 2020, 19 (04)
  • [36] A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis
    Sabahi, Zahra
    Sorkhabi, Amin Daei
    Sarkesh, Aila
    Naseri, Amirreza
    Asghar-Rezaei, Nazli
    Talebi, Mahnaz
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 120
  • [37] Instruments measuring change in cognitive function in multiple sclerosis: A systematic review
    Ezegbe, Chigozie
    Zarghami, Amin
    van der Mei, Ingrid
    Alty, Jane
    Honan, Cynthia
    Taylor, Bruce
    BRAIN AND BEHAVIOR, 2023, 13 (06):
  • [38] Real-World Persistence with Ocrelizumab in Multiple Sclerosis: a Systematic Review
    Petrie, John L.
    Smith, Charlie A.
    Fountain, Donna
    Machnicki, Gerardo
    NEUROLOGY AND THERAPY, 2024, 13 (06) : 1597 - 1605
  • [39] Gustatory dysfunction in multiple sclerosis: a systematic review and meta-analysis
    Firouzabadi, Shahryar Rajai
    Mohammadi, Ida
    Alinejadfard, Mohammadreza
    Panah, Mohammad Yazdan
    Vaheb, Saeed
    Shaygannejad, Vahid
    Mirmosayyeb, Omid
    CHEMICAL SENSES, 2025, 50
  • [40] Cost-effectiveness of natalizumab in multiple sclerosis: an updated systematic review
    Koeser, Leonardo
    McCrone, Paul
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (02) : 171 - 182